ASBP

0.292

1.68% 0.0068

Handel nachbörslich: .29 -0.002 -0.68%

Aspire Biopharma Holdings Inc (ASBP)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

$0.2852

Offen:

$0.2805

24-Stunden-Volumen:

607.34K

Relative Volume:

0.05

Marktkapitalisierung:

$19.75M

Einnahmen:

Nettoeinkommen (Verlust:

KGV:

EPS:

Netto-Cashflow:

1W Leistung:

-5.23%

1M Leistung:

-24.48%

6M Leistung:

+0.00%

1J Leistung:

+0.00%

1-Tages-Spanne:

$0.28

$0.3082

1-Wochen-Bereich:

$0.2571

$0.33

52-Wochen-Spanne:

$0.215

$2.10

Aspire Biopharma Holdings Inc Stock (ASBP) Company Profile

Firmenname

Aspire Biopharma Holdings Inc

Sektor

Healthcare (1169)

Branche

Biotechnology (655)

Telefon

561-704-8527

Adresse

194 CANDELARO DRIVE, #233, HUMACAO

Mitarbeiter

Twitter

Nächster Verdiensttermin

Neueste SEC-Einreichungen

ASBP's Discussions on Twitter

Vergleichen Sie ASBP mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ASBP Aspire Biopharma Holdings Inc	0.292	19.75M	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	459.62	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	547.36	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	331.91	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	543.48	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	245.49	28.51B	3.81B	-644.79M	-669.77M	-6.24

Aspire Biopharma Holdings Inc Aktie (ASBP) Neueste Nachrichten

Jun 18, 2025

Aspire Biopharma Holdings relocates headquarters to Florida - Investing.com

Jun 18, 2025

Aspire Biopharma Relocates Executive Office to Florida - TipRanks

Jun 18, 2025

Jun 10, 2025

Michael Howe takes helm as CEO of Aspire Biopharma By Investing.com - Investing.com South Africa

Jun 10, 2025

Aspire Biopharma Holdings, Inc., Announces Michael C. HoweWith Decades of Experience at Leading and Building Brands in the Healthcare and Consumer SpaceTo Be Its New Chief Executive Officer - El Paso Times

Jun 10, 2025

Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - The Columbus Dispatch

Jun 09, 2025

Jun 02, 2025

Aspire Biopharma (NASDAQ:ASBP) Rating Lowered to Strong Sell at Wall Street Zen - Defense World

Jun 02, 2025

May 29, 2025

ASBP Stock Price and Chart — NASDAQ:ASBP - TradingView

May 29, 2025

Pre-market Movers: ALZN, HCTI, REVB, NTLA... - RTTNews

May 29, 2025

Aspire Biopharma provides development update on BUZZ BOMB supplement - Yahoo Finance

May 29, 2025

Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025 - Akron Beacon Journal

May 29, 2025

May 28, 2025

Aspire Biopharma (ASPH) Stock Explodes Over 160%: What's Behind the Monumental Surge? - Daily Chhattisgarh News

May 28, 2025

Pharma Stock Massively Bid Up Following New Product Announcement - The Globe and Mail

May 28, 2025

Aspire Biopharma To Launch BUZZ BOMB Sublingual Pre-Workout; Begins Production And Testing - Nasdaq

May 28, 2025

Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews

May 28, 2025

May 20, 2025

ASBP stock touches 52-week low at $0.22 amid sharp annual decline - Investing.com India

May 20, 2025

Sidoti Events, LLC's Virtual May Micro-Cap Conference - FinancialContent

May 20, 2025

May 19, 2025

Vita Bella Partners with New to The Street for National Media Campaign - Lohud

May 19, 2025

May 16, 2025

Aspire Biopharma announces resale of up to 11.26M shares - MSN

May 16, 2025

May 14, 2025

Aspire Biopharma Holdings, Inc. SEC 10-Q Report - TradingView

May 14, 2025

May 08, 2025

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21 - ACCESS Newswire

May 08, 2025

ASBPAspire Biopharma Holdings Inc Latest Stock News & Market Updates - Stock Titan

May 08, 2025

May 02, 2025